Clinical Evidence

Delve into clinical research studies and more

Clinical research lies at the heart of who we are. Vantive uses scientific evidence systematically, and transparently, to inform the development of new state-of-the-art solutions for patients around the world. Here you can find various studies, white papers and articles concerning important topics across the wide range of therapy areas served by Vantive.

HDx therapy enabled by the Theranova Dialyzer
Efficacy of enoxaparin in preventing coagulation during high-flux haemodialysis, expanded haemodialysis and haemodiafiltration
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Efficacy of expanded hemodialysis at different dialysate flows
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Efficacy of Medium Cut-Off Dialyzer and Comparison with Standard High-Flux Hemodialysis
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Efficacy of medium cut-off dialyzers and comparison with high-flux dialyzers in patients on maintenance hemodialysis: A systematic review and meta-analysis
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
End-Stage Renal Disease, Inflammation and Cardiovascular Outcomes
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Endotoxin Retentive Performance of the Fresenius FX CorAL Dialyzer.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Evaluating a remote patient monitoring program for automated peritoneal dialysis - Ariza J, et al.
Visit resource site
PD
Evaluating the impact of the Claria Sharesource system - Manani, et al.
Download PDF
HDx therapy enabled by the Theranova Dialyzer
Evaluation and comparison of polysulfone TS-UL and PMMA NF-U dialyzers versus expanded hemodialysis and postdilution hemodiafiltration.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Evaluation of Albumin Loss During Hemodialysis with Theranova® Medium Cut-Off (MCO) Dialyzer: Six Months Follow-Up
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Evaluation of the efficacy of a medium cut-off dialyser and comparison with other high-flux dialysers in conventional haemodialysis and online haemodiafiltration
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Evaluation of the influence of the surface membrane and blood flow in medium «cut-off» (MCO) dialyzers
Visit resource site

Important Safety Information

INTENDED USE

The Theranova Dialyzer is indicated for patients with chronic kidney failure who are prescribed intermittent hemodialysis. It provides an expanded solute removal profile with increased removal of various middle molecules (up to 45 kDa) that may play a pathologic role in the uremic clinical syndrome. The Theranova Dialyzer is not intended for hemofiltration or hemodiafiltration therapy. The total extracorporeal blood volume for the Theranova Dialyzer and the set should represent less than 10% of the patient's blood volume.

For single use only.

 

Rx Only. For safe and proper use of the products mentioned herein, please refer to the appropriate Operator’s Manual or Instructions for Use.

 

Vantive, HDx and Theranova are trademarks of Vantive Health LLC or its affiliates.